Articles On Capitol Health (ASX:CAJ)
Title | Source | Codes | Date |
---|---|---|---|
9 ASX shares Goldman Sachs tips to positively surprise this earnings season
Earnings season has now kicked off and countless ASX shares are getting ready to hand in their report cards. Goldman Sachs has been running the rule over the market and has picked out a number of ASX shares as having potential for positive... |
Motley Fool | CAJ | 1 year ago |
‘Best positioned’: 2 ASX mining shares about to explode
There is no getting around that smaller ASX mining shares can be risky. That’s because junior miners are often involved in exploration and that tends to have a binary outcome — you either find the mineral or you don’t. But if you can manag... |
Motley Fool | CAJ | 1 year ago |
Top brokers name 3 ASX shares to buy today
Many of Australiaâs top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Hereâs why the... |
Motley Fool | CAJ | 1 year ago |
Morgans says these are the best ASX growth shares to buy in July
If youâre looking for ASX growth shares to buy, then look no further. Thatâs because Morgans has recently named some among its best ideas for the month of July. Two that make the cut are listed below. Hereâs why it is very bullis... |
Motley Fool | CAJ | 1 year ago |
The disappointing ASX sector now ready for a MASSIVE winter revival
For more than a year now, experts have been saying ASX healthcare shares are the place to park your money. The reasoning is that health is a type of spending that consumers are reluctant to cut back even in times of economic stress. But l... |
Motley Fool | CAJ | 1 year ago |
3 former ASX market darlings now trading at 52-week lows. Are they cheap buys?
Unfortunately for investors, thereâs no guarantee that todayâs market darlings will remain in favour with investors in the future. When companies go through difficult periods, many investors will sell off their holdings and move onto s... |
Motley Fool | CAJ | 1 year ago |
Australian Broker Call *Extra* Edition – Jun 30, 2023
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now... |
FNArena | CAJ | 1 year ago |
2 ‘pleasing’ ASX 200 tech shares to get your hands on right now
While US and Japanese stocks have shot ahead in 2023, the S&P/ASX 200 Index (ASX: XJO) has been left behind. Many experts attribute this to the relatively small presence of the technology sector in the Australian market. The ASX 200 i... |
Motley Fool | CAJ | 1 year ago |
Are beaten-up Bega shares a bargain buy?
Bega Cheese Ltd (ASX: BGA) shares have continued their decline on Thursday. In morning trade, the diversified food companyâs shares have dropped 3% to a new decade-low of $3.02. This means they are now down over 21% since the start of th... |
Motley Fool | CAJ | 1 year ago |
Guess which ASX 200 stock has plunged to a 10-year low
The Bega Cheese Ltd (ASX: BGA) share price was in a world of pain on Wednesday, cascading to its lowest level in almost a decade. Bega’s bitter performance stood out like a sore thumb against a backdrop of the S&P/ASX 200 Index (ASX: X... |
Motley Fool | CAJ | 1 year ago |
Why Bega Cheese, Capitol Health, Centaurus Metals, and Seek shares are falling
The S&P/ASX 200 Index (ASX: XJO) is on form again and on course to record a strong gain. In afternoon trade, the benchmark index is up 1.2% to 7,202.1 points. Four ASX shares that have failed to follow the market higher today are lis... |
Motley Fool | CAJ | 1 year ago |
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO
Invex granted orphan drug designation in Europe Resonance Health has a new CEO EBR to raise $35m as it eyes market launch Invex Therapeutics (ASX:IXC) announced the granting of orphan drug designation (ODD) from the European Medicines A... |
Stockhead | CAJ | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | CAJ | 1 year ago |
MoneyTalks: Why Goldman recommends these two ASX stocks in the booming diagnostic imaging space
Goldman has Buy recommendations for health imaging stocks Capitol Health and Integral Diagnostics Capitol Health’s earnings multiple is cheap, says Goldman Integral is currently Goldman’s cheapest stock across its coverage Goldman Sachs... |
Stockhead | CAJ | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | CAJ | 1 year ago |
Goldman Sachs has just slapped buy ratings on these ASX healthcare shares
If youâre wanting exposure to the healthcare sector, then it could be worth listening to what Goldman Sachs is recommending at this side of the market. It has been looking at the services side of the sector and has picked out two ASX hea... |
Motley Fool | CAJ | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | CAJ | 1 year ago |
‘Highly sought-after’: 3 ASX healthcare shares ready to roar again
In turbulent times such as now, ASX healthcare shares have typically been in favour. After all, even when high inflation or rising interest rates eat into spending power, consumers still want to take care of their physical and mental well-... |
Motley Fool | CAJ | 1 year ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | CAJ | 1 year ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | CAJ | 1 year ago |
79% upside: The ‘frustrating’ ASX share waiting to take off
The efficient market hypothesis says share prices always reflect all available information about the businesses. However, veteran ASX investors would know that in reality that’s not necessarily true. Sometimes the market just fails to full... |
Motley Fool | CAJ | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | CAJ | 1 year ago |
A note to young investors part 2: How to invest in quality growth stocks
In part one of this note to young investors, I set out the reasons why I think young investors should steer clear of index funds and instead invest in high-quality, growing companies. So, the question is: how to find and invest in these com... |
Montgomery | CAJ | 1 year ago |
2 ASX shares to buy that no one talks about
You want your portfolio to perform better than the market, right? If not, then you might as well just buy passive ETFs and be done with it. The whole point of owning a basket of company-specific stocks is because you want better returns t... |
Motley Fool | CAJ | 1 year ago |
S&P500 rises on hopes that the worst of bank crisis is over
ShareCafeS&P500 rises on hopes that the worst of bank crisis is over The S&P 500 rose Thursday, as investors bet the worst of the regional bank crisis has passed. Weekly jobless claims increased by 7,000 to... |
ShareCafe | CAJ | 1 year ago |
The Overnight Report: Not With A Bang
World Overnight SPI Overnight 7177.00 – 21.00 – 0.29% S&P ASX 200 7258.40 + 33.60 0.47% S&P500 3970.15 – 12.09 – 0.30% Nasdaq Comp 11455.54 – 11.44 – 0.10% DJIA 32656.70 – 232.39 – 0.71% S&P500 VIX 20.70 – 0.25 – 1... |
FNArena | CAJ | 1 year ago |
Despite a solid start for stocks, major US indexes fall in Feb
ShareCafeDespite a solid start for stocks, major US indexes fall in Feb The major averages fell on Tuesday to round out a tough month for the stock market. Despite a solid start to the year, the major indexes are on... |
ShareCafe | CAJ | 1 year ago |
The Overnight Report: Range-Bound?
World Overnight SPI Overnight 7201.00 + 34.00 0.47% S&P ASX 200 7224.80 – 82.20 – 1.12% S&P500 3982.24 + 12.20 0.31% Nasdaq Comp 11466.98 + 72.04 0.63% DJIA 32889.09 + 72.17 0.22% S&P500 VIX 20.95 – 0.72 – 3.32%... |
FNArena | CAJ | 1 year ago |
FNArena Corporate Results Monitor – 24-02-2023
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Metals ((AX1)) - Accent Group ((ACF)) - Acrow Formwork and Construction Services ((A1M)) - AIC Mines ((AIZ)) - Air New Zealand ((APA)) - APA Group ((AIA)) - Au... |
FNArena | CAJ | 1 year ago |
Australian Broker Call *Extra* Edition – Feb 10, 2023
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now... |
FNArena | CAJ | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | CAJ | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | CAJ | 1 year ago |
Australian Broker Call *Extra* Edition – Nov 24, 2022
An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au... |
FNArena | CAJ | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | CAJ | 1 year ago |
18 Share Tips – 21 November 2022
Braden Gardiner, Tradethestructure BUY RECOMMENDATIONS Capitol Health (CAJ) CAJ provides diagnostic imaging and related services to the healthcare market. Revenue of $184.2 million in fiscal year 2022 was up 3.5 per cent on the prior corres... |
TheBull | CAJ | 1 year ago |
3 small-cap ASX shares that drove fund up 35% while the market plunged
Ask A Fund Manager The Motley Fool chats with the best in the industry so that you can get an insight into how the professionals think. In this edition, 1851 Capital portfolio manager Martin Hickson names three ASX shares investors should... |
Motley Fool | CAJ | 1 year ago |
Top fund manager has ‘never seen’ ASX share price moves like we are witnessing
The S&P/ASX 200 Index (ASX: XJO) is a sea of calm relative to some of the extreme volatility witnessed in the S&P/ASX Small Ordinaries Index (ASX: XSO), particularly among the smallest companies in that index. Writing in its Octobe... |
Motley Fool | CAJ | 1 year ago |
Retail investors switching to cash: Tesla under pressure
ShareCafeRetail investors switching to cash: Tesla under pressure Stocks fell in choppy trading on Thursday as investors weighed several key earnings reports and kept an eye on the bond market, where Treasury yields... |
ShareCafe | CAJ | 1 year ago |
Metaverse stocks struggling, as bond yields head towards 4%
ShareCafeMetaverse stocks struggling, as bond yields head towards 4% Stocks were lower on Tuesday as investors braced for another large rate hike due out Wednesday from the Federal Reserve. The Dow Jones Industrial... |
ShareCafe | CAJ | 1 year ago |
3 ASX All Ords shares going ex-dividend on Wednesday
The end of ASX reporting season in August has led to a number of companies in the S&P/ASX All Ordinaries Index (ASX: XAO) turning ex-dividend this month. When an ASX All Ords share turns ex-dividend, investors buying these shares wonâ... |
Motley Fool | CAJ | 1 year ago |
2 little-known ASX shares that this fund manager says have ‘strong’ outlooks
Wilson Asset Management (WAM) is one fund manager that likes to hunt for smaller ASX shares that could have solid investment outlooks. WAM runs a number of different listed investment companies (LICs) including WAM Capital Limited (ASX: WA... |
Motley Fool | CAJ | 1 year ago |
FNArena Corporate Results Monitor – 26-08-2022
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIZ)) - Air New Zealand ((AKE)) - Allkem ((CAJ)) - Capitol Health ((CHC)) - Charter Hall ((CCX)) - City Chic Collective ((CBL)) - Control Bionics ((DTC)) - Damstra Holdi... |
FNArena | CAJ | 2 years ago |
‘Simply too cheap’ ASX share that could plough ahead in a recession: expert
With interest rates rising, many experts are urging investors to buy ASX shares that can maintain revenue through tough times. One such sector is health, where the logic is that Australians will still need to treat their illnesses and inju... |
Motley Fool | CAJ | 2 years ago |
Australian Broker Call *Extra* Edition – Jul 21, 2022
An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au... |
FNArena | CAJ | 2 years ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | CAJ | 2 years ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | CAJ | 2 years ago |
Brokers rate these 2 top ASX shares as buys in May 2022
Can you believe May 2022 is here already? There are a number of ASX shares brokers rate as buys this month. This article is about two smaller businesses that could be opportunities for investors to consider. Here are two buy-rated stocks:... |
Motley Fool | CAJ | 2 years ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | CAJ | 2 years ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | CAJ | 2 years ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | CAJ | 2 years ago |